

## Sunday, July 12

10:00-18:30 Registration open

### I. Atypical hemolytic uremic syndrome (aHUS)

*Chairs: Kronenberg, Speth*

13:00 L1 aHUS – Role of complement, overview  
*Meri, FI*

13:30 L2 aHUS – Role of lectin pathway and coagulation  
*Garred, DK*

14:00 L3 aHUS – Spectrum of mutations  
*Roumenina, FR*

14:30-15:00 Coffee break

### II. Atypical hemolytic uremic syndrome (aHUS)

*Chairs: Stoiber, Prohaszka*

15:00 L4 aHUS – Novel insights into pathogenesis  
*Licht, CA*

15:30 L5 aHUS – Endothelial cell integrity and complement  
*Riedl, CA*

16:00 FC1 Comprehensive genetic analysis by next generation sequencing (NGS) in a cohort of 264 patients with aHUS  
*Bachmann et al.*

16:15 FC2 Laboratory evaluation and the prospective diagnosis of thrombotic microangiopathies: case-series study of 540 patients  
*Szilágyi et al.*

16:30 FC3 Genotypic and phenotypic studies of a novel factor B mutation in familial aHUS  
*Aradottir et al.*

16:45 FC4 Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor I autoantibodies in aHUS  
*Nozal et al.*

17:00-17:30 Coffee break

### III. E. coli associated Hemolytic uremic syndrome (eHUS)

*Chairs: Orth-Höller, Rosales*

- 17:30 L6 SPECIAL LECTURE  
eHUS & Shiga toxin – the early days  
Karmali, CA
- 18:00 L7 Shiga toxin – from gut to kidneys  
Brigotti, IT
- 18:30 L8 Shiga toxin effects – evidence from animal studies  
Obata, JP

19:00 Welcome reception at the Congresspark Igls

**Monday, July 13**

**III. E. coli associated hemolytic uremic syndrome (eHUS) & complement**

*Chairs: Lass-Flörl, Jozsi*

- 08:30 L9 Alternative pathway and podocytes  
*Morigi, IT*
- 09:00 L10 Complement control proteins and coagulation  
*Orth-Höller, AT*
- 09:30 FC5 Long-term follow-up of children with STEC-HUS caused by  
*E. coli* O104:H4 (German HUS outbreak 2011): a GPN  
registry  
*Aulbert et al.*
- 09:45 FC6 The complement system is altered on serological and  
genetic level in both infection-induced and complement-  
mediated HUS  
*Westra et al.*

10:00-10:30 Coffee break

**IV. Other HUS forms**

*Chairs: Gaedicke, Schneeberger*

- 10:30 L11 Post transplant HUS – alloantibodies & endothelial injury  
*M. Stegall, US*
- 11:00 L12 BMTx associated thrombotic microangiopathy  
*S. Jodele, US*
- 11:30 FC7 A 17 year experience of *Streptococcus pneumoniae*  
associated HUS; clinical features and outcome compared  
with diarrheal HUS  
*Wong et al.*
- 11:45 FC8 Eleven pregnancies in four women with aHUS  
*Gaggl et al.*

12:00-13:00 Lunch break

13:00 **Poster session with dessert**

*Chairs: Martini, Giner, Waldegger, Kropshofer, Rudnicki, Würzner*

## V. Clinical courses of aHUS and related disorders – 4 cases

*Chairs: N. Van de Kar, Jungraithmayr*

- |       |    |  |
|-------|----|--|
| 14:30 | C1 | HUS as the first presentation of SLE in a 18-year old boy<br><i>Jedzura et al.</i>   |
| 14:45 | C2 | aHUS associated with a mutation in MCP<br><i>Manrique et al.</i>   |
| 15:00 | C3 | Late case<br>NN  |
| 15:15 | C4 | Severe retinal involvement in a child with aHUS and positive outcome associated with eculizumab: retinal and renal improvement in parallel<br><i>Martin-Begué et al.</i> |

15:30-16:00 Coffee break

## VI. C3 glomerulopathy (C3G)

*Chairs: Mayer, Brunner*

- |       |      |  |
|-------|------|--|
| 16:00 | L13  | C3G – consensus report<br><i>M. Pickering, UK</i>  |
| 16:30 | L14  | C3G – role of the factor H related family<br><i>P. Zipfel, DE</i>  |
| 17:00 | FC9  | Defective C3 complement regulation by autoimmune C3 glomerulopathy: do complement inhibitors affect complement control by autoantibodies?<br><i>Schulze et al.</i> |
| 17:15 | FC10 | Renin cleavage of C3: a kidney-specific mechanism of complement activation<br><i>Békássy et al.</i>  |

19:00 Tyrolean night at the Sporthotel Igls

**Tuesday, July 14**

**VII. Treatment and monitoring I**

Chairs: *Riedl, Weigel*

- 08:30 L15 Treatment of aHUS with eculizumab - studies  
*C. Bedrosian, US*
- 09:00 L16 Treatment of aHUS with eculizumab – clinical experiences  
*C. Loirat, FR*
- 09:30 FC11 aHUS – different pathologies, individual therapies  
*Habbig et al.*
- 09:45 FC12 Eculizumab as first-line treatment of pediatric aHUS  
*Román-Ortiz et al.*
- 10:00 FC13 Differential effects of eculizumab in diagnostic assays to measure complement activity  
*Hamann, Wouters et al.*
- 10:15 FC14 Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in aHUS  
*Volokhina et al.*

10:30-11:00 Coffee break

**VIII. Treatment & monitoring II**

Chairs: *Hofer, Ariceta*

- 11:00 L17 Monitoring eculizumab therapy  
*M. Noris, IT*
- 11:30 L18 Treatment of anti-factor H-associated HUS  
*A. Baqqa, IN*
- 12:00 Concluding remarks  
*R. Würzner, AT*

12:30-14:00 Farewell and lunch